CBL0137

• UNSPSC Description:

  CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF- B and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis[1].

• Target Antigen:

  Histone Acetyltransferase; MDM-2/p53; NF-κB

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Epigenetics;NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/CBL-0137.html

• Purity:

  99.68

• Solubility:

  DMSO : 11.11 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC(NCCN1C2=C(C3=C1C=CC(C(C)=O)=C3)C=C(C(C)=O)C=C2)C

• Molecular Weight:

  336.43

• References & Citations:

  [1]Barone TA, et al. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Neuro Oncol. 2017 Feb 1;19(2):186-196. h|[2]Burkhart C, et al. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 2014 Nov 30;5(22):11038-53.|[3]Ehteda A, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021 Apr 13;35(2):108994.Cell Death Dis. 2024 Oct 27;15(10):779.|Eur J Med Chem. 2024 Apr 15:270:116377.|Adv Mater. 2024 Jul;36(29):e2313991.|Cancer Res. 2021 Jun 1;81(11):3105-3120.|Cell Death Dis. 2020 Dec 2;11(12):1029.|Cell. 2024 Dec 26;187(26):7533-7550.e23.|Mol Med Rep. 2024 Nov;30(5):209.|Oncogene. 2022 Nov 10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Phase 2

• CAS Number:

  1197996-80-7